​

Immunome (IMNM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

IMNM Stock Forecast

Immunome (IMNM) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $36.33, with a high of $40.00 and a low of $32.00. This represents a 100.06% increase from the last price of $18.16.

$10 $16 $22 $28 $34 $40 High: $40 Avg: $36.33 Low: $32 Last Closed Price: $18.16

IMNM Stock Rating

Immunome stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 0 13 Strong Sell Sell Hold Buy Strong Buy

IMNM Price Target Upside V Benchmarks

TypeNameUpside
StockImmunome100.06%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts3311
Avg Price Target$35.33$35.33$33.73
Last Closing Price$18.16$18.16$18.16
Upside/Downside94.55%94.55%85.74%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 26312---15
May, 26211---13
Apr, 26212---14
Mar, 26212---14
Feb, 26211---13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 28, 2026Supawat ThongthipTruist Financial$37.00$22.1167.35%103.74%
May 28, 2026Lukas ShumwayBarclays$36.00$22.1162.82%98.24%
May 15, 2026Andrew BerensLeerink Partners$33.00$22.0249.86%81.72%
Feb 12, 2026H.C. Wainwright$40.00$23.4170.87%120.26%
Dec 16, 2025Lake Street$32.00$23.3936.81%76.21%
Dec 16, 2025Evercore ISI$40.00$23.3571.31%120.26%
Dec 15, 2025Leerink Partners$40.00$22.6576.60%120.26%
Dec 01, 2025Karina RabayevaTruist Financial$36.00$18.4295.44%98.24%
Nov 17, 2025Stephens$33.00$17.1492.53%81.72%
Sep 05, 2025Craig-Hallum$26.00$10.52147.15%43.17%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 28, 2026BarclaysOverweightinitialise
Feb 12, 2026H.C. WainwrightBuyinitialise
Dec 16, 2025Lake StreetBuyBuyhold
Dec 16, 2025Evercore ISIOutperformOutperformhold
Dec 16, 2025GuggenheimBuyBuyhold
Sep 22, 2025Goldman SachsBuyinitialise
Sep 05, 2025Craig-HallumBuyinitialise
Aug 22, 2025Evercore ISIOutperforminitialise
Nov 14, 2024Piper SandlerOverweightOverweighthold
Sep 16, 2024Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.38$-5.00$-2.43---
Avg Forecast$-0.92$-4.42$-3.11$-3.21$-2.81$-1.32
High Forecast$-0.47$-4.32$-2.48$-2.36$-1.72$-1.01
Low Forecast$-1.19$-4.56$-4.10$-4.36$-3.97$-1.63
Surprise %484.78%13.12%-21.86%---

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$14.02M$9.04M$6.94M---
Avg Forecast$12.27M$9.41M$3.15M$17.90M$76.14M$223.12M
High Forecast$14.02M$11.40M$3.71M$17.90M$76.14M$262.84M
Low Forecast$10.50M$7.56M$2.58M$17.90M$76.14M$183.11M
Surprise %14.28%-3.89%120.50%---

Net Income Forecast

$-300M $-240M $-180M $-120M $-60M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-106.81M$-292.96M$-212.39M---
Avg Forecast$-16.47M$-88.13M$-65.26M$-66.63M$-56.45M$-26.19M
High Forecast$-9.41M$-85.78M$-49.16M$-46.75M$-34.13M$-20.09M
Low Forecast$-23.53M$-90.47M$-81.35M$-86.51M$-78.77M$-32.26M
Surprise %548.56%232.44%225.47%---

IMNM Forecast FAQ

Is Immunome stock a buy?

Immunome stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Immunome is a favorable investment for most analysts.

What is Immunome's price target?

Immunome's price target, set by 13 Wall Street analysts, averages $36.33 over the next 12 months. The price target range spans from $32 at the low end to $40 at the high end, suggesting a potential 100.06% change from the previous closing price of $18.16.

How does Immunome stock forecast compare to its benchmarks?

Immunome's stock forecast shows a 100.06% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Immunome over the past three months?

  • June 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 15.38% Strong Buy, 84.62% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Immunome’s EPS forecast?

Immunome's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.21, marking a 32.10% increase from the reported $-2.43 in 2025. Estimates for the following years are $-2.81 in 2027, and $-1.32 in 2028.

What is Immunome’s revenue forecast?

Immunome's average annual revenue forecast for its fiscal year ending in December 2026 is $17.9M, reflecting a 157.95% increase from the reported $6.94M in 2025. The forecast for 2027 is $76.14M, and $223.12M for 2028.

What is Immunome’s net income forecast?

Immunome's net income forecast for the fiscal year ending in December 2026 stands at $-66.63M, representing a -68.63% decrease from the reported $-212M in 2025. Projections indicate $-56.449M in 2027, and $-26.194M in 2028.